Literature DB >> 28871002

Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes.

Sangsu Shin1, Miok Kim2,3, Seon-Jin Lee2, Kang-Seo Park4, Chang Hoon Lee5,3.   

Abstract

BACKGROUND/AIM: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. The ability of HCC to avoid immune detection is considered one of the main factors making it difficult to cure. Abnormal histone deacetylation is thought to be one of the mechanisms for HCC immune escape, making histone deacetylases (HDACs) attractive targets for HCC treatment. Here, we investigated the effect of trichostatin A (TSA), a highly potent HDAC inhibitor, on HCC (HepG2) gene expression and function.
MATERIALS AND METHODS: A genome wide-transcriptional microarray was used to identify genes regulated by TSA in HepG2 cells. Gene Ontology was used to identify pathways regulated by TSA, and these changes were confirmed by qPCR. The effect of TSA on natural killer (NK) cell-mediated killing of HCC cell lines were analyzed by both flow cytometry and LDH cytotoxicity assay. A study was also conducted in a Balb/c nude mice xenograft model to assess the anti-tumor activity of TSA.
RESULTS: TSA regulated the transcription of numerous innate immunity & tumor antigen recognition-associated genes, such as ULBP1 and RAET1G, in HCC cells. In vivo, TSA reduced tumor cell growth in an NK cell-dependent manner. In vitro, TSA treatment of HepG2 cells rendered them more susceptible to NK cell-mediated killing while increasing the expression of NKGD2 ligands, including ULBP1/2/3 and MICA/B. TSA also induced direct killing of HCC cells by stimulating apoptosis.
CONCLUSION: TSA likely increases killing of HCC cells indirectly by increasing NK cell-directed killing and directly by increasing apoptosis. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Natural killer cells; hepatocellular carcinoma; immunotherapy; trichostatin A

Mesh:

Substances:

Year:  2017        PMID: 28871002      PMCID: PMC5611521          DOI: 10.21873/cgp.20045

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  39 in total

1.  Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.

Authors:  Reena Buurman; Engin Gürlevik; Vera Schäffer; Marlies Eilers; Maria Sandbothe; Hans Kreipe; Ludwig Wilkens; Brigitte Schlegelberger; Florian Kühnel; Britta Skawran
Journal:  Gastroenterology       Date:  2012-05-26       Impact factor: 22.682

Review 2.  Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.

Authors:  Christos Damaskos; Nikolaos Garmpis; Serena Valsami; Michael Kontos; Eleftherios Spartalis; Theodoros Kalampokas; Emmanouil Kalampokas; Antonios Athanasiou; Demetrios Moris; Afrodite Daskalopoulou; Spyridon Davakis; Gerasimos Tsourouflis; Konstantinos Kontzoglou; Despina Perrea; Nikolaos Nikiteas; Dimitrios Dimitroulis
Journal:  Anticancer Res       Date:  2017-01       Impact factor: 2.480

3.  Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.

Authors:  Gabriele Imre; Volker Gekeler; Astrid Leja; Thomas Beckers; Markus Boehm
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

Review 4.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

5.  Cross talk between the TM4SF5/focal adhesion kinase and the interleukin-6/STAT3 pathways promotes immune escape of human liver cancer cells.

Authors:  Jihye Ryu; Minkyung Kang; Mi-Sook Lee; Hye-Jin Kim; Seo Hee Nam; Haeng Eun Song; Doohyung Lee; Jung Weon Lee
Journal:  Mol Cell Biol       Date:  2014-06-09       Impact factor: 4.272

6.  The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.

Authors:  Elisabeth Höring; Oliver Podlech; Björn Silkenstedt; Ioanna Alexandros Rota; Eleni Adamopoulou; Ulrike Naumann
Journal:  Anticancer Res       Date:  2013-04       Impact factor: 2.480

7.  Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells.

Authors:  A Nazmul H Khan; Christopher J Gregorie; Thomas B Tomasi
Journal:  Cancer Immunol Immunother       Date:  2007-11-28       Impact factor: 6.968

Review 8.  The concept of immune surveillance against tumors. The first theories.

Authors:  Domenico Ribatti
Journal:  Oncotarget       Date:  2017-01-24

9.  Histone deacetylase inhibitors as novel anticancer therapeutics.

Authors:  D R Walkinshaw; X J Yang
Journal:  Curr Oncol       Date:  2008-10       Impact factor: 3.677

10.  Clinical relevance of circulating mucosal-associated invariant T cell levels and their anti-cancer activity in patients with mucosal-associated cancer.

Authors:  Eun Jeong Won; Jae Kyun Ju; Young-Nan Cho; Hye-Mi Jin; Ki-Jeong Park; Tae-Jong Kim; Yong-Soo Kwon; Hae Jin Kee; Jung-Chul Kim; Seung-Jung Kee; Yong-Wook Park
Journal:  Oncotarget       Date:  2016-11-15
View more
  13 in total

1.  In Vivo Study of Natural Killer (NK) Cell Cytotoxicity Against Cholangiocarcinoma in a Nude Mouse Model.

Authors:  In Hye Jung; DO Hee Kim; DA Kyung Yoo; Sun Young Baek; Seong Hoon Jeong; Dawoon E Jung; Seung Woo Park; Yong-Yoon Chung
Journal:  In Vivo       Date:  2018 Jul-Aug       Impact factor: 2.155

2.  Is There an Opportunity for Current Chemotherapeutics to Up-regulate MIC-A/B Ligands?

Authors:  Kendel Quirk; Shanmugasundaram Ganapathy-Kanniappan
Journal:  Front Pharmacol       Date:  2017-10-17       Impact factor: 5.810

3.  Exploration of prognostic index based on immune-related genes in patients with liver hepatocellular carcinoma.

Authors:  Weidong Shi; Lanyun Feng; Shu Dong; Zhouyu Ning; Yongqiang Hua; Luming Liu; Zhen Chen; Zhiqiang Meng
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

Review 4.  Small-Molecule Targets in Tumor Immunotherapy.

Authors:  Hui-Fang Zhu; Yan Li
Journal:  Nat Prod Bioprospect       Date:  2018-07-05

Review 5.  The role of natural killer cells in hepatocellular carcinoma development and treatment: A narrative review.

Authors:  Sarun Juengpanich; Liang Shi; Yasaman Iranmanesh; Jiang Chen; Zhenzhe Cheng; Aaron Kah-Jin Khoo; Long Pan; Yifan Wang; Xiujun Cai
Journal:  Transl Oncol       Date:  2019-06-06       Impact factor: 4.243

6.  ZNF518B gene up-regulation promotes dissemination of tumour cells and is governed by epigenetic mechanisms in colorectal cancer.

Authors:  Francisco Gimeno-Valiente; Ángela L Riffo-Campos; Azahara Vallet-Sánchez; Sofía Siscar-Lewin; Valentina Gambardella; Noelia Tarazona; Andrés Cervantes; Luis Franco; Josefa Castillo; Gerardo López-Rodas
Journal:  Sci Rep       Date:  2019-06-27       Impact factor: 4.379

7.  New landscapes and horizons in hepatocellular carcinoma therapy.

Authors:  Melchiorre Cervello; Maria R Emma; Giuseppa Augello; Antonella Cusimano; Lydia Giannitrapani; Maurizio Soresi; Shaw M Akula; Stephen L Abrams; Linda S Steelman; Alessandro Gulino; Beatrice Belmonte; Giuseppe Montalto; James A McCubrey
Journal:  Aging (Albany NY)       Date:  2020-02-04       Impact factor: 5.682

Review 8.  Hepigenetics: A Review of Epigenetic Modulators and Potential Therapies in Hepatocellular Carcinoma.

Authors:  Mohamed H Yousef; Hassan A N El-Fawal; Anwar Abdelnaser
Journal:  Biomed Res Int       Date:  2020-11-24       Impact factor: 3.411

9.  A short-chain fatty acid, propionate, enhances the cytotoxic effect of cisplatin by modulating GPR41 signaling pathways in HepG2 cells.

Authors:  Mamiko Kobayashi; Daisuke Mikami; Junsuke Uwada; Takashi Yazawa; Kazuko Kamiyama; Hideki Kimura; Takanobu Taniguchi; Masayuki Iwano
Journal:  Oncotarget       Date:  2018-07-31

Review 10.  Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities.

Authors:  Nikolaos Garmpis; Christos Damaskos; Anna Garmpi; Vasiliki E Georgakopoulou; Panagiotis Sarantis; Efstathios A Antoniou; Michalis V Karamouzis; Afroditi Nonni; Dimitrios Schizas; Evangelos Diamantis; Evangelos Koustas; Paraskevi Farmaki; Athanasios Syllaios; Alexandros Patsouras; Konstantinos Kontzoglou; Nikolaos Trakas; Dimitrios Dimitroulis
Journal:  J Pers Med       Date:  2021-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.